J. DELAY and P. DENIKER** The changes in the therapy of mental disorders since 1952, due to the introduction of new chemotherapeutic substances and more particularly of neuroleptics, have had little effect on the treatment of depressive states, especially melancholia, for which electroshock (ECT) continued to be in most cases the correct indication.
Nevertheless the indications for ECT are limited for various reasons. The depression may appear too mild or the patient and his relatives may refuse the treatment, a situation which seems to arise with increasing frequency. But the main reasons appear to be that this method becomes less and less effective as the depressive phases follow one another, and that its action is only temporary, as in the case of the increasing number of aged patients so treated. There has therefore been a constant search for a method of chemotherapy of the depressive states either by means of sedative drugs (of which laudanum is no doubt the oldest) or by stimulants acting on the nervous system or on the organism as a whole.
Our interest in this problem was aroused as early as 1949, when in view of the findings of Hyden and Hartelius with malonic dinitrile, we suggested the use of succinic dinitrile, a drug still indicated today for the ambulatory treatment of minor depressions. In 1952, one of us, together with Laine and Buisson, had called attention to the anti-depressant therapeutic effect of isoniazid, and also to the psychic complications occurring in patients treated with it for tuberculosis.
With the introduction of chlorpromazine it soon became apparent that while this drug may be effective in curing simple depressions the picture changes radically in melancholia or endogenous depression; here the effect is principally symptomatic as regards insomnia and anxiety, but the fundamental causes of the depression and the mental suffering experienced by the patient remain unaffected. As to reserpine, our observations were even less encouraging; indeed it is well known that the protracted use of this drug may by itself cause depression and even melancholia. Among the newer neuroleptics, there are two which seem to yield better results in the treatment of depressions: levomepromazine, which will be discussed later, and sulfamidophenothiazine (7843 RP), which like ECT in some cases leads to hypomanic mood inversions but also produces true neurologic syndromes and cannot therefore be recommended as a simple therapeutic method for frequent use.
The results achieved with isoniazid caused us to become interested in the propyl derivative of isonicotinic acid introduced by Kline (iproniazid). The accidents which had been reported in America caused an interruption of our clinical experiments in this direction, but we were nevertheless in a position to confirm the 'efficacy of iproniazid in the treatment of endogenous depressions or melancholias insofar as the drug can produce a complete reversal of mood, a result which simple chemotherapy had so far only achieved in exceptional cases.
One of the newer anti-depressant drugs is Tofranil t (imipramine) which differs in chemical composition from both the phenothiazines and isonicotinic acid derivatives. We are indebted to the perseverance of Kuhn for the discovery of the very special properties of this drug as regards depressive states; his findings have since been confirmed by a number of authors, such as Steck and Kielholz in Switzerland, Freyhan and Lehmann on the American continent, Fazio in Italy, and others.
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With the assistance of Lernperiere, Ropert and others, and basing our work on the general indications suggested by the authors named above, we made an analytical study of the clinical psychiatric properties of the drug. It was our purpose a) to define its potentialities with respect to the various forms of depression; b) to compare its efficacy with that of iproniazid and levomepromazine; c) to find whether it is possible to determine the position of the drug in Delay's classification of modern psychotropic drugs, namely psycholeptics or sedatives, psycho-analeptics or stimulants, and psycho-dysleptics or drugs influencing psychic activity.
Methods and Material
It is a recognized fact that any study of depressive states comes up against the problem of arriving at a simple classification of the cases under consideration. The form, evolution and prognosis of each case are dependent upon a great many factors. Though we do not propose to study these factors here, there are two which have special importance: the symptomatology as observed in the patient, and the etiology of the case. The two often overlap, so that a neurotic patient may at times present a true melancholic syndrome while a manic-depressive person may go through an atypical phase resembling a simple depression or hypochondriac condition. For this reason we included a wide variety of cases, each of which was classified both according to the semeiology and to the available etiologic data. Each patient was first placed in a symptomatic classification limited to 5 categories: 1. Simple depressions; 2. Melancholic depressions) 3. Severe melancholias accompanied by agitation, delusions or stupor; 4. Hypochondriac syndromes; 5. Complex depressions, e.g. those accompanying a psychosis. The next step consisted in listing for each case the main etiologic elements gathered from the case history and from an objective appraisal. Nine such elements were decided upon: A. Reactive or exhaustive depressions; B. Depressions with a neurotic or psychasthenic basis; C. Depressions with a psychopathic or psychotic basis; D. Periodic depressions; E. Depressive phase of manic-depressive disease; F. Depressions of hereditary origin; G. Late depressions occurring after the age of 45; H. Depressions with organic nervous disease; 1. Depressions of toxic or endocrine origin.
In this manner, it was possible to identify each case by means of a code, a simple number indicating the semeiologic features and several letters representing the various etiologic elements. As an example, a case of involutional melancholia with signs of organic disease and hereditary cause would be designated by 2 F G H. This system partly overcomes the theoretical difficulty caused by the nature of depressions from the genetic and other aspects.
Of 170 patients treated, 137 were considered suitable for the purposes of our study (all complicated cases were noted). The material included both in-and out-patients and embraced 85 females and 52 males, ranging in age from 19 to 79 years.
Whenever possible, the results of the treatment were recorded daily on a standard form indicating both dosage and the main neuro-vegetative, neurologic and psychic reactions.
Method of Treatrnerrt
Treatment was carried out according to three techniques as follows: 1) a majority of the patients were treated by the methods used by the earlier investigators, i.e. the highest dose was given over about 10 days, by intramuscular injections if possible, and then gradually replaced by oral doses, after which slowly decreasing doses were given exclusively by mouth; 2) in some cases where the neurologic and organic state required more careful handling, the dosage was gradually VolA,1959 increased, levelled off and finally decreased again; 3) Tofranil was administered in combination with neuroleptics (levomepromazine or chlorpromazine) in cases where the anti-depressant drug alone failed to yield satisfactory results or where it was felt that this combination would be more efficient from the start.
Three dosage schedules were used: a normal dosage of 150-200 mg per day, a low dosage of 50-100 mg per day, which seemed more appropriate for older patients, and a high dosage of over 300 mg per day. This latter dose called for considerable caution since most of the severe reactions occurred in cases where it was used.
The duration of the treatment varied from 3 days (in exceptional cases lasting improvement was observed after very brief treatment) to 5 months. Analysis of the results was delayed by the fact that in as many as 40% of the cases the improvement was maintained only by continuing therapy.
Results
The results were evaluated independently by a number of observers and classified as follows: complete remission of the depression (++ +); remission incomplete but still satisfactory to the patient (+ +); marked but inadequate improvement (+); no change, or transient or doubtful effect (0); aggravation (-).
A favorable response often occurs during the first week and is then confirmed after 2-4 weeks, with occasional daily fluctuations. However, the medication has a purely symptomatic effect and maintenance doses must be continued for a long time. In nearly one-half of the cases treatment seems merely to improve the condition until the depressive episode is resolved.
The results have been tabulated and represent the maximum therapeutic effect obtained either with Tofranil alone or in combination with neuroleptic drugs but not with electroshock. This method admittedly detracts from the statistical purity of the results, but had to be adopted owing to the necessity of giving relief to the patients, in the knowledge that in some cases the condition of melancholia represents a real psychiatric emergency. The results given take no account of later relapses.
The complete results for our 137 patients are contained in Table 1 . It will be seen from this table that the proportion of complete remissions is only 22%, but if those substantial improvements which seem satisfactory to the patient even if not to the psychiatrist are added then the proportion reached 60%, which must be compared with the results obtained with iproniazid. The proportion of failures or doubtful improvements, together with aggravations, is less than 20%. In a clas- . . sification according to sex there were no significant differences between males and females. Similarly, statistics relating to in-patients and out-patients did not show any appreciable differences. Full details are shown in the tables which follow. The results arranged according to the symptomatology of the patients treated are given in Table 2 . It will be seen from this table that the best effects are obtained in frank melancholic syndromes, where 74% of patients showed results +++ or ++, while in simple depressions only 54% showed substantial improvements, and in severe melancholias only 53%. The lowest figure (47%) is for depressions superimposed on some other psychosis, that is depressions in patients with delirium, or atypical depressions later diagnosed as schizophrenic. I It is of interest to compare these findings with a rearrangement of the results according to the etiologic factors as has been done in Table 3 . If the complete remissions and substantial improvements are added together, it is seen that the best results obtained are for the depressive phase of manic-depressive disease (75%), while depressions of hereditary origin reach 68%. This means that the most pronounced effects are in those cases which could be classed as manic-depressive psychosis.
Considerable success was also recorded in depressions appearing after the age of 45 years (67%), or accompanied by signs of organic nervous disease (70%), which mainly represent involutional melancholias and organic depressions, such as those of arteriosclerotic patients. The least successful results are in depressions with a neurotic basis (56%) or psychopathic basis (52%), which is in accordance with the findings shown in Table 2 .
The numerical results are amply confirmed by a qualitative clinical evaluation of the patients. The commonest observation is an early improvement, inducing a cooperative attitude by the patient, but then taking a rather slow course. Inhibition and inertia are affected first, mental stress and anxiety are relieved later. In patients who are made worse, fortunately a rare occurrence, anxiety increases and is accompanied by agitation. Even in successful cases insomnia does not disappear at once; often it is aggravated to the extent that barbiturate soporifics have to be given. 
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The drug itself cannot be said to have a euphoric effect, but by inducing a change of mood in depressed patients it causes euphoria and indeed even hypomania, as does electroshock therapy. The reversal in the character of the patient's mood and the reappearance of an interest in.life, which most depressed patients complain that they lack, appears to be a characteristic feature of the action of antidepressant drugs. This fundamental modification is lacking in sedative therapy.
Cornpartson with Other Anti-Depressant Drugs
Iproniazid. As already stated, iproniazid was the most effective anti-depressant substance among the drugs with which we had experimented before using Tofranil, Although only 45 suitable cases were treated, observations were made on the lines described above. A comparison of the overall results (Table 4 ) clearly shows the Table 6 results of this order are over ,$0% in categories D, E, F and G. If the effects of the consecutive use of the two drugs are compared, Tofranil again appears superior: in 16 patients treated consecutively with both compounds, Tofranil proved superior in 11 cases, equally effective in 2 cases and less effective in 3 cases. Leoomepromazine. Several French workers have reported therapeutic success with levomepromazine in depressive states. The most significant and favourable results are those of Letailleur et al., who treated 75 cases. They stress the superiority of the results obtained in cases of simple depressions as compared to severe melancholias, as is usual with the neuroleptics. Nevertheless, of 17 cases of melancholia they report 8 complete remissions and 9 failures or minor improvements, i.e, less than 50% of successes. Our own experience is that even though levomeprornazine sometimes results in a real remission of true melancholia, the results are too inconsistent to be reliable. However, these findings have prompted us to combine phenothiazines with Tofranil in an attempt to improve our results.
Combination of TofraniI with Neuroleptics
The combination of Tofranil with neuroleptics, and particularly with levomepromazine, was found by chance to be advantageous. Patients who had failed to respond to Tofranil reacted very favourably to the combination. In some cases withdrawal tests were significant, withdrawal of the neuroleptic drug causing a relapse and its restoration a renewed improvement.
As already mentioned, the results shown in Tables 1-3 relate to Tofranil alone or to its combinations. Their analysis is not an easy task. As far as the best results (++ +) are concerned, out of 30 patients 15 were cured by Tofranil alone and 15 by a combination. Of 52 markedly improved cases (+ +), 23 were treated with Tofranil alone and 29 with a combination. These figures are clearly not significant, but it must be borne in mind that a fair proportion of the good results obtained with a combination of neuroleptics and Tofranil were subsequent to complete or partial failure of the latter. Tables 7 and 8 show the results with 40 cases treated first with Tofranil alone and then after one or two weeks with a combination of Tofranil and neuroleptics, Table 7 shows the overall therapeutic effects in the 40 cases under review. It will be seen that in 23 of these 40 cases there was a change from poor to satisfactory results (separated by a double line) as a consequence of the introduction of the combined therapy. In 14 cases no change occurred; in 13 others one category of symptoms was affected, in 9 cases 2 such categories and in 4 other cases 3 such categories. It should be borne in mind, however, that the prolongation of Tofranil treatment alone might also have been successful. Table 8 shows an analysis of the results by syndromic groups. It will be seen that the change from poor to good categories is particularly marked where simple or melancholic depressions and severe melancholias are concerned.
Comparison between Tofranfl Treatment and ECT
Comparative results of treatment with Tofranil and with ECT cannot be submitted for the reason that the majority of our cases had either failed to respond to ECT or its use was not justified from the start.
Qualitatively speaking, however, there are many differences between the results obtained by the two methods. Although the action of Tofranil is prompt it is nevertheless slower than that of ECT; the latter seems more effective in severe melancholias where treatment is a matter of real urgency. On the whole there are more similarities in the effects produced than differences, bearing in mind that what is essential is the capacity to bring about a complete 'change in the mood of the patient.
However, the indications for the two methods of treatment are not quite the same. Those for Tofranil may be summarized as follows: (a) The immediate use of Tofranil is justified in the milder forms of depression, where ECT does not appear necessary; this is true even though these milder forms are not those which respond most readily to chemotherapy. (b) Tofranil is also appropriate in conditions which fail to respond to ECT treatment or become resistant to it. This is notably the case in recurrent presenile depressions. It has already been found possible to combine Tofranil with ECT but it cannot yet be said that chemotherapy permits a reduction in the number of shock treatments, although this is our impression. This would be the case in theory, since the continuation of ECT is primarily intended to prevent relapses, a result which may be achieved by chemotherapy, presumably even where the latter had proved inadequate initially. S108 CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL Vol. 4, 1959 Among our 137 cases, 19 were given ECT after Tofranil, alone or in combination, had been found inadequate, with the following result: (a) The effect of ECT was poor (+) or nil (0) in 5 cases, 2 with typical and 3 with severe melancholia. ECT never caused aggravation. (b) In 5 cases (l of typical melancholia, 2 of severe melancholia, 1 of hypochondria and 1 of depression with psychotic background) there was marked improvement (++).
(c) Complete remission (++ +) was obtained in 9 cases, 2 of simple depression, 4 of typical melancholia and 3 of severe melancholia.
On the whole there are few cases of depression which prove resistant to both Tofranil and ECT.
Side Effects
Side effects are extremely frequent but usually of moderate intensity. They rarely interfere with the course of treatment.
Patients complain of various discomforts: dryness of the mouth (one-third of the cases), difficulties of accommodation (one-quarter of the cases, particularly aged persons), dizziness especially when changing position (one-fifth of the cases) and which may even cause the patient to fall when suddenly moving his head. The gait is sometimes unsteady. Other subjective symptoms such as headaches, asthenia, paresthesia, cramps, a feeling of "inner trembling," are less frequent and difficult to assess in patients with anxiety.
The tendency to insomnia has already been mentioned and is often seen in the early stages of treatment. It may call for the use of sleep-inducing drugs. More rarely, patients experience sleepiness in the daytime.
Neuro-vegetative disorders are common: excessive sweating (one-third of the cases), particularly at night, hot flushes, constipation, intense thirst. These disorders are more marked in the early stages of treatment and tend to lessen in intensity later on. Cardiovascular symptoms are very irregular; many patients mention palpitations but there are no objective indications. Hypotension is often observed, however, especially in aged and hypertensive patients. Its importance dictates special caution when using the drug in older patients or those with arteriosclerosis.
Digestive tolerance is good: only 3 patients complained of nausea or vomiting. Cutaneous tolerance is less good: 7 patients developed generalized pruritus, and 2 others transient erythema in various locations. On 9 occasions marked glossitis, with or without stomatitis or sore throat, was observed.
Neurologic symptons are very common: tendinous hyper-reflectivity without clonic spasm or polykinetism (13 cases); muscular twitchings, myoclonia or fasciculations (20 cases); tremors of many different forms (45 cases) such as very fine and quick tremor of tongue and hands, resembling emotional tremor, slower tremor in a resting position with crumbling movements of the fingers but without either muscular hypertonicity or tremors of large amplitude. Dysarthria is comparatively frequent, and micrographia occurs at times. Dysuria occurred in only 2 cases.
On two occasions epileptic fits were observed. In a woman of 38 a generalized convulsion occurred on the 29th day of treatment: this patient had been given large oral doses ofT6franii of up to 400 mg per day, together with 100 mg of chlorpromazine and 50 mg of promethazine. During the days preceding the convulsion, she had shown a strong generalized tremor. In the second case, a woman of 46 suffered 3 generalized convulsions on the 22nd day of the treatment, followed by stupor lasting 24 hours, with a transient left-side Babinski's reflex. This patient had been four days on a 400 mg daily dose without additional neuroleptics. For some days she had been complaining of dizziness, visual disorders, tremors and dysarthria. Both these patients later received Tofranil at lower dosage and showed excellent results.
In 3 patients episodes of dream-like confusion occurred on a dosage of 250 to 300 mg per day. On decreasing the dosage the symptoms disappeared in two of these cases (one male aged 49 and one female aged 65). In the third case, an arteriopathic woman of 56, renewed treatment caused repeated hallucinatory disorders. It should be noted that 3 other patients stated that they experienced visual hallucinations which were clearer with the eyes closed and occurred mostly before falling asleep (colours, small human forms, landscapes). Finally, the inversions of mood observed never went beyond a certain euphoria or very slight hypomania; the frequent use of neuroleptics, however, may have contributed to this decreased effect.
Electroencephalography
The electroencephalograms (by Dr. Verdeaux) which will be discussed in a later publication, have in general shown that Tofranil produces a marked increase in amplitude of the basic alpha rhythm or a re-synchronization of the latter where before treatment it had been de-synchronized or of low voltage. . When the dosage is increased there is a tendency to hypersynchronization and the pattern slowly becomes acute and "irritative". This occurs only in patients receiving more than 75 mg per day.
This tendency of certain patterns to become "irritative" is a warning that a low dosage should be given to patients whose spontaneous pattern is of this type, for example vascular patients.
Position of Tofrarril in the Classification of Psychotropic Drugs
The investigations which led to the introduction of Tofranil were initially undertaken in an effort to find new neuroleptics or tranquilizers. This is in line with the neuro-vegetative changes observed, as also with the numbness or somnolence sometimes experienced by patients in the initial stages of treatment.
If an attempt is made to classify the drug according to its main clinical effects it seems inappropriate to place it among the "thymoleptics" (literally drugs which "depress the mood") since its essential action appears to be "thyme-analeptic" in that it is a mood-stimulant. Observations of the effects of Tofranil on normal persons are not yet available, however.
As we have seen, although the neurologic 'effects of the drug are by no means negligible, there is no clear-cut syndrome like that characteristic of the neuroleptics. At most there are hyper-reflectivity, tremors and twitchings. The convulsions sometimes observed at high dosage and the electroencephalographic patterns of "irritative" type are quite characteristic of the drug. The mood reversal with expansive euphoria and the occasional hallucinatory complications are similar to the effects observed with isoniazid and iproniazid. The therapeutic action of Tofranil is comparable with that of the isonicotinic acid derivatives, although the former is clearly more effective and easier to control.
It seems appropriate to class these drugs together as anti-depressive agents falling within the category of psycho-analeptics. Up to now this category of psychotropic drugs was composed essentially of the psychotonic amines whose principal effect is stimulation of wakefulness and anti-hypnotic. However, wakefulness is not the only factor governing the general psychic condition and it is clear that mood regulation also plays a major part.
Psycholeptics or psychic stimulants may therefore be subdivided into 2 groups: (a) stimulants of wakefulness or anti-hypnotics, and (b) mood stimulants Vol. 4,1959 or anti-depressives. The complete classification of modern psychotropic drugs proposed by Delay is therefore as follows:
1. Psycholeptics: a) hypnotics b) neuroleptics c) tranquilizers.
Psycho-analeptics:
a) stimulants of wakefulness or anti-hypnotics b) mood stimulants or anti-depressives. 3. Psycho-dysleptics. However, this classification must not be regarded as a clear-cut one. Some of the "psychotonic" agents may under certain conditions become psycho-pathogenic or dysleptic; some of the newly discovered neuroleptics may be stimulants; and Tofranil may be considered to have a secondary sedative effect in addition to its principal stimulant effect. Conclusions 1. Tofranil is today the most effective chemotherapeutic drug for the treatment of those depressive states which have hitherto remained relatively unresponsive to simple medication. . 2. Good and very good results are usually observed in more than 50% of the cases treated. The highest percentage is found in endogenous, melancholic, presenile and organic depressions, all of which have previously been indications for electroshock treatment.
3. The action of the new drug is somewhat similar to that of electroshock insofar as it can radically modify the depressive mood. Since its action is slower and milder, the indications are somewhat different, and its first use should be in slight or moderate depressions. Long-term therapy with the drug is also possible and this makes it particularly effective in recurrent or lingering depressive states.
4. The combination with neuroleptics, in particular with levomepromazine, seems to reinforce the action of Tofranil, and improves the results obtained.
5. Therapy is easily managed and although there are many side effects, complications rarely arise. Reactions occur mostly at high dosage or in patients more vulnerable because of age or hereditary factors.
6. Since the principal action of the drug is anti-depressant and mood-regulating, Tofranil should be classed among the psycho-analeptics or psychic stimulants. 7. Its effectiveness, ease of management and essentially suspensive action indicate that the drug will find long and extensive use, but the attendant risks should be properly weighed if it is to be used by physicians with little psychiatric experience.
Resmne
En rappelant l'inefficacite relative des chimiotherapies neuroleptiques a l'egard des etats depressifs, les auteurs enumerent res medications qui ont ete recemment proposees, avant l'introduction du Tofranil, La difficulte de l'experimentation clinique tient a la multiplicite et a la complexite des etats qu'on peut ranger sous le terme de depression. On a done adopte une classification a double entree comportant d'une part un classement syndromique et d'autre part l'indication des elements etiologiques releves, Les resultats, portant sur 137 cas utilisables, sont ensuite exposes en fonction de ces modes de classement. Les meilleurs succes concernent non seulement les depressions simples deja influencees par diverses therapeutiques, mais aussi les etats S1I1 melancoliques et depressions endogenes qui justifiaient l'emploi de I'electrochoc, sans que ceux-ci aient definitivemenr disparus. L' association de la levomepromazine a la cure de Tofranil semble constituer un reel progres du point de vue des resultats quantitatifs et qualitatifs. La comparaison des resultats obtenus avec Ie Tofranil est envisagee avec d'autres substances comme les neuroleptiques et les derives de l'acide isonicotinique. Un certain nombre d'observations privilegiees permettent de preciser l'aspect qualitatif du nouveau traitement et son incidence sur divers types de depressions.
L'examen des effets secondaires est d'une grande importance pour la defini- Hardly any chemotherapeutic agent has escaped critical analysis by the group at the Sainte-Anne Hospital as soon as it was introduced for clinical use. Professor Delay and Dr. Deniker have provided us with thorough studies on almost all new drugs which are actually used in the treatment of psychiatric conditions. Their opinion is always awaited eagerly. It is based on definition and description of disease entities which have made the French school of psychiatry famous for almost 200 years. Their opinion is characteristically based upon strict criteria, careful analysis and perspective. All possible variables are taken into consideration and it is clear that the authors have a thorough knowledge of the neurophysiology of the brain. It is obvious that the present paper belongs in this same category and utilizes the same criteria. This explains its great value and unquestionable usefulness for all clinicians.
The results presented by Dr. Deniker could hardly be more encouraging. We too are forced to conclude that Tofranil represents a new and powerful weapon which is easily administered and whose side effects are easily controlled. Despite this important discovery, further studies are necessary to prevent loss of perspective with regard to the danger involved in the treatment of depressions. Within this framework, we have to consider the therapeutic approach and the remaining problems which have to be solved.
With regard to the dangers, we should first mention the danger of suicide. It is well known that this problem always has to be considered in the depressed patient, especially during a period of improvement immediately following institution of therapy. It is necessary therefore that regular medication in appropriate amounts be assured during such a phase if we wish to prevent accidents.
Th'e risk of inappropriate treatment should also be considered. As the number of psychotropic drugs increases, the danger is also increased that psychiatric treatment may become over-simplified. If we are not careful, many clinicians may risk becoming "empiricists" who do not pay the necessary attention to signs and symptoms or to psychiatric observations, which remain as always the basis and the prerequisite of true therapy. Without such strictness and patience, our clinicians also risk becoming "cooks" of psychiatry, completely preoccupied with prepared recipes, adjusting day by day their learned mixture of sedatives, neuroleptics, psycho tonics, thymoleptics, etc., solely because of changing symptoms observed during superficial examination.
This means that new ideas are required, indeed as many as possible, and they must be carefully weighed and discussed. Chemotherapy should not eliminate psychotherapy. It should be possible to interpret the dynamics of the psyche in neurophysiological terms. Hereditary and constitutional ele- VolA,1959 ments should be properly evaluated within the framework of a complete developmental history of the individual and his clinical status. The signs and symptoms should always be critically reviewed so that the best therapeutic approach can be made.
It follows that every patient should be viewed within the framework of his whole existence. This imposes on our science the necessity to develop simultaneously in all directions and to visualize the remaining problems which have to be solved within their mutual relationship. In looking at the forest, one may perhaps never recognize the trees, but if one's outlook is too limited, the trees may be mistaken for the forest.
The presentation of Dr. Deniker shows that there are still numerous problems to be solved. For example the differential diagnosis of the many types of depressions still presents great difficulties. The fact that symptoms and etiological elements are listed in the same table certainly permits eloquent comparisons, but may not represent a final answer to the many questions created by nosological classification. Our experience has to be enlarged, our descriptions have to accumulate, comparisons must be made, and quarrels between schools of thinking must yield to objectivity before we can draw an adequate picture of the many types of depression.
Similarly, if it is true that Tofranil acts on inhibition and inertia, one should try to explain its lack of action in a certain number (25%) of cases with frank melancholy, where inhibition and inertia dominate the syndrome.
In hospitalized patients who benefit from the action of Tofranil, it would be interesting to distinguish the part played by the drug, the part attributed to the return to the social and family environment as compared to the hospital, and the part played by psychotherapy, with or without the patient's knowledge, performed by the hospital staff. Finally one can ask how these secondary effects can help us to determine the site and mode of action of Tofranil.
It should be emphasized that Tofranil is much more suitable than electroshock therapy for investigating the depressive state. Electroshock constitutes after all a generalized and rapid mode of therapy, where the experimental variables are difficult to control. There is no doubt that the experience gathered by investigators interested in the action of Tofranil permits better separation of the different variables involved, and also permits consideration of the multiplicity of levels at which the action of the patient and the therapist take place. In this important field of research we eagerly await further contributions from the group at Sainte-Anne Hospital.
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